Skip to main content
. Author manuscript; available in PMC: 2017 Apr 3.
Published in final edited form as: Crit Care Med. 2016 Feb;44(2):275–281. doi: 10.1097/CCM.0000000000001402

Figure 1.

Figure 1

Treatment with IL-1Ra significantly improves 28-day survival in HBD/DIC sepsis, but does not change the outcome in non-HBD/DIC sepsis.

HBD: hepatobiliary dysfunction

DIC: disseminated intravascular coagulation

rIL-1Ra: anakinra (abbreviation for recombinant interleukin-1 receptor antagonist)

HBD/DIC group: patients with severe sepsis who demonstrate BOTH HBD and DIC features

Non-HBD/DIC group: patients with either HBD alone (no DIC), DIC alone (no HBD, or neither.

Statistically significant pP value is set at 0.05.